The purpose of this report is to investigate antibacterial activities of sulfamethoxazole (SMX) -trimethoprim (TMP) combination product together with evaluation of its clinical efficacy in obstetrics and gynecological patients. Activities of the combination of SMX-TMP were found to be enhanced by potentiation against clinically isolated Staphylococci, Escherichia coli and Proteus strains. Concentrations of this combination product in specimens of blood, urine and milk were assessed by employing thin layer chromatography. The results indicated that the combination product was absorbed relatively promptly and excreted well through the kidney.
A clinical trial was conducted in a total of 42 patients with bacterial infections. The response in 5/7 patients with pelvic infections, 3/3 of puerperal mastitis, 2/4 patients with abscess of external genitalia and 22/28 patients with urinary tract infections was classified as effective (effective rate 78. 5%).
In view of its pharmacokinetic and bacteriological characteristics, this antimicrobial agent appears to be an effective drug particularly suitable for the treatment of urinary tract infections.
